JP2023536746A5 - - Google Patents
Info
- Publication number
- JP2023536746A5 JP2023536746A5 JP2023507951A JP2023507951A JP2023536746A5 JP 2023536746 A5 JP2023536746 A5 JP 2023536746A5 JP 2023507951 A JP2023507951 A JP 2023507951A JP 2023507951 A JP2023507951 A JP 2023507951A JP 2023536746 A5 JP2023536746 A5 JP 2023536746A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- peptide according
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062971P | 2020-08-07 | 2020-08-07 | |
| US63/062,971 | 2020-08-07 | ||
| PCT/US2021/033189 WO2022031342A1 (en) | 2020-08-07 | 2021-05-19 | Tau vaccine for the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536746A JP2023536746A (ja) | 2023-08-29 |
| JP2023536746A5 true JP2023536746A5 (https=) | 2024-05-28 |
Family
ID=80118379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507951A Pending JP2023536746A (ja) | 2020-08-07 | 2021-05-19 | アルツハイマー病の処置のためのタウワクチン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230302127A1 (https=) |
| EP (1) | EP4192583A4 (https=) |
| JP (1) | JP2023536746A (https=) |
| KR (1) | KR20230080398A (https=) |
| CN (1) | CN117751132A (https=) |
| AR (1) | AR122129A1 (https=) |
| AU (1) | AU2021321206A1 (https=) |
| CA (1) | CA3188458A1 (https=) |
| IL (1) | IL300346A (https=) |
| MX (1) | MX2023001501A (https=) |
| TW (1) | TW202221022A (https=) |
| WO (1) | WO2022031342A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN115894659B (zh) * | 2022-10-19 | 2023-11-10 | 上海优宁维生物科技股份有限公司 | 微管相关蛋白Tau抗原及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106390107B (zh) * | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| JP2013500326A (ja) * | 2009-07-30 | 2013-01-07 | ファイザー バクシーンズ エルエルシー | 抗原性タウペプチドおよびその使用 |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| JP6654899B2 (ja) * | 2013-12-26 | 2020-02-26 | 東亞合成株式会社 | カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド |
| WO2015165961A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| US20180050097A1 (en) * | 2015-03-25 | 2018-02-22 | Stc. Unm | Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse |
| KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| KR102784294B1 (ko) * | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| SG11202001826YA (en) * | 2017-10-16 | 2020-03-30 | Adjuvance Technologies Inc | Triterpene saponin analogues |
| EP3894438A1 (en) * | 2018-12-13 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
| JP7630834B2 (ja) * | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
-
2021
- 2021-05-19 MX MX2023001501A patent/MX2023001501A/es unknown
- 2021-05-19 US US18/020,037 patent/US20230302127A1/en active Pending
- 2021-05-19 AU AU2021321206A patent/AU2021321206A1/en active Pending
- 2021-05-19 IL IL300346A patent/IL300346A/en unknown
- 2021-05-19 CA CA3188458A patent/CA3188458A1/en active Pending
- 2021-05-19 WO PCT/US2021/033189 patent/WO2022031342A1/en not_active Ceased
- 2021-05-19 JP JP2023507951A patent/JP2023536746A/ja active Pending
- 2021-05-19 KR KR1020237007892A patent/KR20230080398A/ko active Pending
- 2021-05-19 CN CN202180068044.6A patent/CN117751132A/zh active Pending
- 2021-05-19 TW TW110118155A patent/TW202221022A/zh unknown
- 2021-05-19 AR ARP210101372A patent/AR122129A1/es unknown
- 2021-05-19 EP EP21854646.3A patent/EP4192583A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526500A5 (https=) | ||
| JP2023536746A5 (https=) | ||
| JP2023541669A5 (https=) | ||
| JP2023541670A5 (https=) | ||
| JP2023536995A5 (https=) | ||
| JP2011529084A5 (https=) | ||
| US10596238B2 (en) | Methods and compositions related to immunogenic fibrils | |
| KR20000005429A (ko) | 비수지성 주쇄 펩티드 담체 | |
| US20030175285A1 (en) | Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid | |
| JP2023541671A5 (https=) | ||
| US11285204B2 (en) | Tobamovirus-based virus-like particles and vaccines | |
| JP2012523379A (ja) | 免疫原性組成物およびその使用 | |
| JP2022514411A (ja) | リポペプチドビルディングブロックおよび合成ウイルス様粒子 | |
| US20230372461A1 (en) | Immunogenic peptides, compositions, and methods for the treatment and/or prevention of malaria | |
| US20050049197A1 (en) | Induction of immune response against desired determinants | |
| JP3057748B2 (ja) | 細胞毒性ｔリンパ球の特異的誘導用合成ワクチン | |
| AU2016201589B2 (en) | Peptide adjuvants | |
| Gras-Masse | Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations | |
| WO2004011486A2 (fr) | Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse | |
| JP2024538615A5 (https=) | ||
| CN119894531A (zh) | Tau肽免疫原构建体 | |
| JP5931113B2 (ja) | 免疫原性組成物およびその使用 | |
| CN118660717A (zh) | 抗α-突触核蛋白的治疗性疫苗 | |
| FR2842812A1 (fr) | Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse | |
| KR20080004445A (ko) | 절단형 ｌｈｒｈ 포뮬레이션 |